Señales en vivo de 688180.SS | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (30 abr 2024 @ 03:00):

Stats
Volumen de hoy	16.81M
Volumen promedio	6.39M
Capitalización de mercado	24.90B
EPS	CNY0 ( 2023-10-26 )
Próxima fecha de ganancias	( CNY0 ) 2024-06-28
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-12.99
ATR14	CNY0.0520 (0.17%)

Volumen Correlación

Largo: 0.36 (neutral)

Corto: 0.82 (strong)

Signal:(44.594) Same movement expected

Shanghai Junshi Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Shanghai Junshi Correlación - Moneda/Commodity

0.32
( neutral )

-0.07
( neutral )

0.00
( neutral )

0.31
( neutral )

-0.80
( moderate negative )

-0.09
( neutral )

Shanghai Junshi Finanzas

Annual	2023
Ingresos:	CNY1.48B
Beneficio Bruto:	CNY698.62M (47.11 %)
EPS:	CNY-2.32

FY	2023
Ingresos:	CNY1.48B
Beneficio Bruto:	CNY698.62M (47.11 %)
EPS:	CNY-2.32

FY	2022
Ingresos:	CNY1.45B
Beneficio Bruto:	CNY927.21M (63.79 %)
EPS:	CNY-2.81

FY	2021
Ingresos:	CNY4.02B
Beneficio Bruto:	CNY2.77B (68.74 %)
EPS:	CNY-0.871

Financial Reports:

No articles found.

Shanghai Junshi

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.